Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds
1999
New Insights into Cancer Drug Mechanisms
publication
Evidence: moderate
Author Information
Author(s): Hille B van, Clerc X, Creighton A M, Hill B T
Primary Institution: Division de Cancérologie, Centre de Recherche Pierre Fabre
Hypothesis
The study investigates the role of topoisomerase I and RAD52 proteins in the action of bisdioxopiperazine compounds.
Conclusion
The study provides evidence that topoisomerase I and RAD52 proteins are involved in the mechanism of action of bisdioxopiperazine compounds, which act differently from other known inhibitors.
Supporting Evidence
- The study established a new screening procedure in yeast for drug discovery.
- TOP1 and RAD52 proteins were shown to be involved in the action of bisdioxopiperazine compounds.
- The assay allowed for the identification of anticancer agents based on their effects on specific proteins.
Takeaway
Scientists found that certain proteins in yeast help understand how new cancer drugs work.
Methodology
A functional assay was developed using yeast to identify the effects of various anticancer agents based on specific protein expressions.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website